摘要
目的探讨EML4-ALK、BRCA1基因多态性对晚期非小细胞肺癌EGFR-TKIs治疗疗效及患者预后的影响。方法选取晚期非小细胞肺癌患者共83例,检测所有患者的EML4-ALK及BRCA1基因类型,对比各基因型患者的疾病控制率以及1年内的生存情况。结果所有患者共检测出EML4-ALK阳性10例,其中V1型7例、V2型3例。所有患者的BRCA1分型包括:Ser/Gly 50例、Ser/Ser 20例、Gly/Gly 13例。EML4-ALK阳性患者的疾病控制率与阴性患者无明显差别(P>0.05)。各BRCA1基因型患者的疾病控制率由高到低依次为Ser/Gly、Ser/Ser、Gly/Gly(P<0.05)。EML4-ALK阳性患者的1年无进展生存率以及1年总生存率与EML4-ALK阴性患者比较无明显差别(P>0.05);BRCA1基因的3种分型患者两两比较显示,Ser/Gly患者的1年无进展生存率高于Ser/Ser及Gly/Gly患者(P<0.05),Ser/Ser及Gly/Gly患者的1年无进展生存率比较无明显差别(P>0.05)。Ser/Gly患者的1年总生存率高于Ser/Ser患者(P<0.05),而与Gly/Gly患者比较无明显差别(P>0.05);Ser/Ser患者的1年总生存率与Gly/Gly患者比较无明显差别(P>0.05)。结论EML4-ALK阳性不会影响EGFR-TKIs对晚期非小细胞肺癌患者的治疗效果及预后,BRCA1基因多态性可影响晚期非小细胞肺癌EGFR-TKIs的治疗效果及患者预后。
Objective To discuss the effect of echinoderm microtubule-associated protein-like 4(EML4)-anaplastic lymphoma kinase(ALK)/breast cancer susceptibility gene 1(BRCA1)gene polymorphism on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)in advanced non-small cell lung cancer and patient prognosis.Methods 83 patients with advanced non-small cell lung cancer were selected,and EML4-ALK and BRCA1 variants of all patients were tested,and the disease control rate and 1-year survival rate were compared among different genotypes.Results Among all patients,10 cases were positive for EML4-ALK,including 7 cases of type V1 and 3 cases of type V2.BRCA1 typing included 50 cases of Ser/Gly,20 cases of Ser/Ser,and 13 cases of Gly/Gly.The disease control rate in EML4-ALK-positive patients was not significantly different from that in negative patients(P>0.05).The disease control rate among patients with different BRCA1 genotypes was the highest in Ser/Gly,followed by Ser/Ser,and was the lowest in Gly/Gly(P<0.05).The 1-year progression free survival rate and 1-year overall survival rate yielded no statistical difference between EML4-ALK positive patients and EML4-ALK negative patients(P<0.05).Ser/Gly patients had a higher 1-year progression-free survival rate than Ser/Ser and Gly/Gly patients(P<0.05),while the 1-year progression-free survival rate demonstrated no statistical difference between Ser/Ser patients and Gly/Gly patients(P>0.05).The 1-year overall survival rate was higher in Ser/Gly patients than in Ser/Ser patients(P<0.05),while there was no significant difference in comparison between Ser/Gly patients and Gly/Gly patients(P>0.05).The 1-year overall survival rate of Ser/Ser patients showed no significant difference with that of Gly/Gly patients(P>0.05).Conclusion The efficacy and prognosis of patients with advanced non-small cell lung cancer receiving EGFR-TKIs therapy are not affected by EML4-ALK positivity but by BRCA1 gene polymorphism.
作者
申晓燕
马耀先
李伟
孙桢
方晓瑞
骆许静
SHEN Xiaoyan;MA Yaoxian;LI Wei(Xuchang Central Hospital,Xuchang,461000)
出处
《实用癌症杂志》
2024年第8期1228-1231,共4页
The Practical Journal of Cancer
基金
河南省卫生健康委员会项目(编号:LHGJ20210944)。
